Fernando González‐Ortiz

2.0k total citations · 2 hit papers
34 papers, 458 citations indexed

About

Fernando González‐Ortiz is a scholar working on Physiology, Psychiatry and Mental health and Molecular Biology. According to data from OpenAlex, Fernando González‐Ortiz has authored 34 papers receiving a total of 458 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Physiology, 19 papers in Psychiatry and Mental health and 10 papers in Molecular Biology. Recurrent topics in Fernando González‐Ortiz's work include Alzheimer's disease research and treatments (22 papers), Dementia and Cognitive Impairment Research (18 papers) and Traumatic Brain Injury and Neurovascular Disturbances (4 papers). Fernando González‐Ortiz is often cited by papers focused on Alzheimer's disease research and treatments (22 papers), Dementia and Cognitive Impairment Research (18 papers) and Traumatic Brain Injury and Neurovascular Disturbances (4 papers). Fernando González‐Ortiz collaborates with scholars based in Sweden, United Kingdom and United States. Fernando González‐Ortiz's co-authors include Kaj Blennow, Thomas K. Karikari, Przemysław R. Kac, Henrik Zetterberg, Wagner S. Brum, Nicholas J. Ashton, Peter Harrison, Michael Turton, Jasmine Rivolta and Claudia Saraceno and has published in prestigious journals such as SHILAP Revista de lepidopterología, Brain and Neurology.

In The Last Decade

Fernando González‐Ortiz

29 papers receiving 452 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Brain-derived tau: a novel blood-based biomarker for Alzheimer’s disease-type neurodegeneration

2022 134 citations Fernando González‐Ortiz, Michael Turton et al. profile →
Plasma phospho-tau in Alzheimer’s disease: towards diagnostic and therapeutic trial applications

2023 120 citations Fernando González‐Ortiz, Przemysław R. Kac et al. Molecular Neurodegeneration profile →

Peers

Countries citing papers authored by Fernando González‐Ortiz

Since Specialization

Citations

This map shows the geographic impact of Fernando González‐Ortiz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fernando González‐Ortiz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fernando González‐Ortiz more than expected).

Fields of papers citing papers by Fernando González‐Ortiz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fernando González‐Ortiz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fernando González‐Ortiz. The network helps show where Fernando González‐Ortiz may publish in the future.

Co-authorship network of co-authors of Fernando González‐Ortiz

This figure shows the co-authorship network connecting the top 25 collaborators of Fernando González‐Ortiz. A scholar is included among the top collaborators of Fernando González‐Ortiz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fernando González‐Ortiz. Fernando González‐Ortiz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Plasma levels of the neuron damage markers brain-derived tau and glial fibrillary acidic protein in Lyme neuroborreliosis: A longitudinal study 2025 ·Ticks and Tick-borne Diseases ·(unknown), Fernando González‐Ortiz, (unknown), Åse Bengård Andersen, (unknown), Ulf Andréasson, Kaj Blennow, Helene Mens, Henrik Zetterberg, Anne‐Mette Lebech	0
2	Associations Between Changes in Levels of Phosphorylated Tau and Severity of Cognitive Impairment in Early Alzheimer Disease 2025 ·Neurology ·Fernando González‐Ortiz, Bjørn‐Eivind Kirsebom, (unknown), (unknown), Lene Pålhaugen, Knut Waterloo, Per Selnes, (unknown), Berglind Gísladóttir, Arvid Rongve, Ragnhild Eide Skogseth, Geir Bråthen, Dag Aarsland, Michael Turton, Peter Harrison, Henrik Zetterberg, Sylvia Villeneuve, Tormod Fladby, Kaj Blennow	3
3	Cerebrospinal fluid proteome profiling across the Alzheimer’s disease continuum: a step towards solving the equation for ‘X’ 2025 ·Molecular Neurodegeneration ·(unknown), Mathias Sauer, Laia Montoliu‐Gaya, Andréa L. Benedet, Nicholas J. Ashton, Fernando González‐Ortiz, Joel Simrén, Nesrine Rahmouni, Cécile Tissot, Joseph Therriault, Stijn Servaes, Jenna Stevenson, Ville Leinonen, Tuomas Rauramaa, Mikko Hiltunen, Pedro Rosa‐Neto, Kaj Blennow, Henrik Zetterberg, (unknown)	1
4	Blood biomarkers for brain injury in chronic subdural hematomas: postoperative dynamics and relation to long-term outcome 2025 ·Journal of neurosurgery ·Teodor Svedung Wettervik, Caroline Lindblad, (unknown), (unknown), Fernando González‐Ortiz, Kaj Blennow, (unknown), Jimmy Sundblom	0
5	The plasma p‐tau217/BD‐tau ratio improves biomarker short‐term variability in memory clinic patients 2025 ·Alzheimer s & Dementia Translational Research & Clinical Interventions ·(unknown), Fernando González‐Ortiz, (unknown), (unknown), Henrik Zetterberg, Kaj Blennow, Steen Gregers Hasselbalch, Kristian Steen Frederiksen, Anja Hviid Simonsen	0
6	Cost-effectiveness of diagnosing and treating patients with early Alzheimer's disease with anti-amyloid treatment in a clinical setting 2025 ·Journal of Alzheimer s Disease ·Anders Wimo, Ron Handels, Kaj Blennow, Bjørn‐Eivind Kirsebom, Per Selnes, (unknown), Andreja Emeršič, Fernando González‐Ortiz, Milica G. Kramberger, Anders Sköldunger, (unknown), (unknown), Eleonora M. Vromen, Pieter Jelle Visser, Bengt Winblad, Tormod Fladby	4
7	Mapping Alzheimer’s disease pathology using free water through integrated analysis of plasma biomarkers, microstructural DTI metrics, and macrostructural MRI measures 2025 ·SHILAP Revista de lepidopterología ·Bo Hyun Kim, (unknown), Sung Hoon Kang, Hyemin Jang, (unknown), Yuhyun Park, Henrik Zetterberg, Kaj Blennow, Fernando González‐Ortiz, Nicholas J. Ashton, Sung Tae Kim, Hee Jin Kim, Duk L. Na, (unknown), Sang Won Seo	1
8	Plasma p‐tau217 identifies cognitively normal older adults who will develop cognitive impairment in a 10‐year window 2025 ·Alzheimer s & Dementia ·(unknown), Fernando González‐Ortiz, Nicholas J. Ashton, Christine Déry, Cherie Strikwerda‐Brown, Frédéric St‐Onge, Valentin Ourry, Michael Schöll, Maiya R. Geddes, Simon Ducharme, Maxime Montembeault, Pedro Rosa‐Neto, Jean‐Paul Soucy, John C.S. Breitner, Henrik Zetterberg, Kaj Blennow, Judes Poirier, Sylvia Villeneuve	8
9	Plasma phosphorylated-tau217 is increased in Niemann–Pick disease type C 2024 ·Brain Communications ·Fernando González‐Ortiz, Thomas K. Karikari, Daniëlle te Vruchte, Dawn Shepherd, Bjørn‐Eivind Kirsebom, Tormod Fladby, Frances M. Platt, Kaj Blennow	7
10	Relationships between medical comorbidities and plasma biomarkers of Alzheimer's disease reflect increased pathological markers as well as biological variabilities 2024 ·Alzheimer s & Dementia ·Eun Hye Lee, Sung Hoon Kang, Young Ju Kim, Henrik Zetterberg, Kaj Blennow, Fernando González‐Ortiz, (unknown), Heejin Yoo, (unknown), Jun Pyo Kim, Hee Jin Kim, Duk L. Na, Hyemin Jang, Sang Won Seo	1
11	Neuronal plasma biomarkers in acute ischemic stroke 2024 ·Journal of Cerebral Blood Flow & Metabolism ·(unknown), Fernando González‐Ortiz, Thomas K. Karikari, Bjørn‐Eivind Kirsebom, (unknown), (unknown), Hlin Kvartsberg, Ole Morten Rønning, Berglind Gísladóttir, Kaj Blennow, Tormod Fladby	6
12	Plasma Alzheimer's disease biomarker variability: Amyloid‐independent and amyloid‐dependent factors 2024 ·Alzheimer s & Dementia ·Eun Hye Lee, Sung Hoon Kang, (unknown), Young Ju Kim, Henrik Zetterberg, Kaj Blennow, Fernando González‐Ortiz, Nicholas J. Ashton, (unknown), Heejin Yoo, (unknown), (unknown), Jun Pyo Kim, Hee Jin Kim, Duk L. Na, Hyemin Jang, Sang Won Seo, (unknown)	8
13	Biomarkers of tau phosphorylation state are associated with the clinical course of multiple sclerosis 2024 ·Multiple Sclerosis and Related Disorders ·Andreja Emeršič, Thomas K. Karikari, Przemysław R. Kac, Fernando González‐Ortiz, Maciej Dulewicz, Nicholas J. Ashton, (unknown), (unknown), Jörg Hanrieder, Henrik Zetterberg, Uroš Rot, Saša Čučnik, Kaj Blennow	2
14	Plasma brain‐derived tau correlates with cerebral infarct volume 2024 ·Journal of Internal Medicine ·Fernando González‐Ortiz, Lukas Holmegaard, Björn Andersson, Cecilia Brännmark, Christian Blomstrand, Henrik Zetterberg, Katarina Jood, Kaj Blennow, Christina Jern, Tara M. Stanne	2
15	Preanalytical stability of plasma/serum brain‐derived tau 2023 ·Alzheimer s & Dementia ·Fernando González‐Ortiz, (unknown), Michael Turton, Rui Magalhães, Przemysław R. Kac, Manuel Correia, Peter Harrison, Henrik Zetterberg, Luı́s F. Maia, Kaj Blennow, Thomas K. Karikari	9
16	Association of Serum Brain-Derived Tau With Clinical Outcome and Longitudinal Change in Patients With Severe Traumatic Brain Injury 2023 ·JAMA Network Open ·Fernando González‐Ortiz, Maciej Dulewicz, Nicholas J. Ashton, Przemysław R. Kac, Henrik Zetterberg, (unknown), (unknown), Jörg Hanrieder, Michael Turton, Peter Harrison, Bengt Nellgård, Thomas K. Karikari, Kaj Blennow	16
17	Longitudinal blood biomarker trajectories in preclinical Alzheimer's disease 2023 ·Alzheimer s & Dementia ·(unknown), Nicholas J. Ashton, Cherie Strikwerda‐Brown, Laia Montoliu‐Gaya, Thomas K. Karikari, Przemysław R. Kac, Fernando González‐Ortiz, (unknown), Pierre‐François Meyer, Frédéric St‐Onge, Michael Schöll, Jean‐Paul Soucy, John C.S. Breitner, Henrik Zetterberg, Kaj Blennow, Judes Poirier, Sylvia Villeneuve	32
18	Plasma phospho-tau in Alzheimer’s disease: towards diagnostic and therapeutic trial applications breakdown → 2023 ·Molecular Neurodegeneration ·Fernando González‐Ortiz, Przemysław R. Kac, Wagner S. Brum, Henrik Zetterberg, Kaj Blennow, Thomas K. Karikari	120
19	Levels of plasma brain‐derived tau and p‐tau181 in Alzheimer's disease and rapidly progressive dementias 2023 ·Alzheimer s & Dementia ·Fernando González‐Ortiz, Thomas K. Karikari, (unknown), Simone Baiardi, Angela Mammana, Michael Turton, Przemysław R. Kac, Andrea Mastrangelo, Peter Harrison, Sabina Capellari, Henrik Zetterberg, Kaj Blennow, Piero Parchi	11
20	Diagnostic value of serum versus plasma phospho-tau for Alzheimer’s disease 2022 ·Alzheimer s Research & Therapy ·Przemysław R. Kac, Fernando González‐Ortiz, Joel Simrén, (unknown), Eugeen Vanmechelen, Henrik Zetterberg, Kaj Blennow, Nicholas J. Ashton, Thomas K. Karikari	49

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact